394 related articles for article (PubMed ID: 30198805)
1. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine.
Keshavan P; Pellegrini M; Vadivelu-Pechai K; Nissen M
Expert Rev Vaccines; 2018 Oct; 17(10):865-880. PubMed ID: 30198805
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
[TBL] [Abstract][Full Text] [Related]
3. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
[TBL] [Abstract][Full Text] [Related]
5. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.
Klein NP; Block SL; Essink B; Barbi S; Smolenov I; Keshavan P
Vaccine; 2019 Jul; 37(32):4460-4467. PubMed ID: 31279564
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
[TBL] [Abstract][Full Text] [Related]
7. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
[TBL] [Abstract][Full Text] [Related]
8. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
[TBL] [Abstract][Full Text] [Related]
9. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.
Klein NP; Reisinger KS; Johnston W; Odrljin T; Gill CJ; Bedell L; Dull P
Pediatr Infect Dis J; 2012 Jan; 31(1):64-71. PubMed ID: 22094635
[TBL] [Abstract][Full Text] [Related]
12. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):273. PubMed ID: 20224545
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger EC; Meyer S; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(2):105-14. PubMed ID: 25483566
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.
Lalwani S; Agarkhedkar S; Gogtay N; Palkar S; Agarkhedkar S; Thatte U; Vakil H; Jonnalagedda R; Pedotti P; Hoyle M; Bhusal C; Arora A
Int J Infect Dis; 2015 Sep; 38():36-42. PubMed ID: 26166699
[TBL] [Abstract][Full Text] [Related]
15. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
17. MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.
Tipton M; Daly W; Senders S; Block SL; Lattanzi M; Mzolo T; Barbi S; Pellegrini M; Keshavan P
Vaccine; 2019 Sep; 37(42):6171-6179. PubMed ID: 31495595
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of fractional dose intradermal injection of two quadrivalent conjugated meningococcal vaccines.
Jonker EFF; van Ravenhorst MB; Berbers GAM; Visser LG
Vaccine; 2018 Jun; 36(26):3727-3732. PubMed ID: 29778515
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM.
Kim HW; Park IH; You S; Yu HT; Oh IS; Sung PS; Shin EC; Kim KH
Yonsei Med J; 2016 Nov; 57(6):1511-6. PubMed ID: 27593883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
